

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/650,253	08/27/2003	Zheng J. Li	PC11724D	PC11724D 7178	
28523	7590 03/16/2006	03/16/2006 EXAMINER			
PFIZER INC	- ·	PESELEV, ELLI			
PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD GROTON, CT 06340			ART UNIT	PAPER NUMBER	
			1623		

DATE MAILED: 03/16/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		LA III III N		
		Application No.	Applicant(s)	
		10/650,253	LI ET AL.	
	Office Action Summary	Examiner	Art Unit	
		Elli Peselev	1623	
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address	
WHIC - Exter after - If NO - Failu Any I	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATES as one of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tirr vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. nely filed the mailing date of this communication. D (35 U.S.C. § 133).	
Status				
2a)⊠	Responsive to communication(s) filed on <u>21 Fe</u> This action is FINAL . 2b) This Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro		
Dispositi	on of Claims			
5) □ 6) ☑ 7) □ 8) □ Applicati 9) □	Claim(s) 125 and 128-144 is/are pending in the 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) 125 and 128-144 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or on Papers The specification is objected to by the Examiner	vn from consideration. relection requirement.		
	The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Ex	drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).	
Priority u	ınder 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
2) Notica 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa		

Application/Control Number: 10/650,253

Art Unit: 1623

Claims 125 and 128-144 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement for the reasons stated in the Office Action of September 12, 2005.

Applicant's arguments filed February 21, 2006 have been fully considered but they are not persuasive.

Applicant point out that the azithromycin in the claimed pharmaceutical dosage form is crystalline azithromycin monohydrate hemi-ethanol solvate. This argument has not been found persuasive since applicant has failed to explain how a crystalline compound can retain its crystalline structure once it is dissolved in a aqueous carrier or diluent.

Claims 125 and 128-144 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Bright (U.S. Patent No. 4,474,768) for the reasons set forth in the Office Action of September 12, 2005.

Applicant's arguments filed February 21, 2006 have been fully considered but they are not persuasive.

The crystalline azithromycin monohydrate hemi-ethanol solvate once dissolved in a carrier or diluent is nothing more than azithromycin in a carrier or diluent as disclosed by Bright.

Claims 125 and 128-144 are rejected under 35 U.S.C. 103(a) as being unpatentable over Singer et al (U.S. Patent No. 6,365,574) in view of Curatolo et al (U.S. Patent No. 5,605,889) for the reasons set forth in the Office Action of February 7, 2006.

Application/Control Number: 10/650,253

Art Unit: 1623

Applicant's arguments filed February 21, 2006 have been fully considered but they are not persuasive.

The Declaration submitted by RichardTodd Darrington has been considered but has not been found persuasive since it shows a composition of ethanol solvate in combination with Miglyol 812 but fails to show dosage form of the said composition.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elli Peselev whose telephone number is (571) 272-0659. The examiner can normally be reached on 8.00-4.30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia Jiang can be reached on (571) 272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/650,253

Art Unit: 1623

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Elli Peselev

ELLI PESELEV
PRIMARY EXAMINER
CROUP 1200

Page 4